CareDx, Inc

CareDx, Inc

CDNA

$54.31

Updated: 24/09/2026, 14:56:12

Market Cap
$2.81B
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Country
US
Stock valuation chart
One-year closing share-price history for CDNA
Company Profile

CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.

USD
NASDAQ
CEO: John Walter Hanna Jr.
Employees: 763
https://www.caredx.com
Asset Summaries
Latest generated summaries for CDNA

No summaries found.

Detailed business
Structured knowledge from the latest official annual filing.
No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.
Full company information
Latest profile, trading, valuation, and identifier data stored for CDNA.
Share price
$54.31
Market cap
$2.81B
Exchange
NASDAQ
Currency
USD
CEO
John Walter Hanna Jr.
Employees
763
IPO date
17/07/2014
Beta
2.43
Last dividend
$0.00
Day range
$54.00 – $57.16
52-week range
$13.95 – $57.16
1-day performance
-3.86%
1-year performance
289.32%
Current drawdown (1Y)
-4.99%
CIK
0001217234
CUSIP
14167L103
ISIN
US14167L1035
Created
07/12/2025, 03:14:21
Last update
24/09/2026, 14:56:12

Track CareDx, Inc with an AI analyst

See which prediction-market events move CDNA, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to CDNA from your Railway `news_articles` table.